

Author: Vivekanand V.V. Sreenivas Rao D. Vaidyanathan G. Sekhar N.M. Avijit Kelkar S. Ramachandra Puranik P.
Publisher: Elsevier
ISSN: 0731-7085
Source: Journal of Pharmaceutical and Biomedical Analysis, Vol.33, Iss.5, 2003-12, pp. : 879-889
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content




Imatinib mesylate promising for CML
Inpharma, Vol. 1, Iss. 1303, 2001-01 ,pp. :






Imatinib mesylate: response in hypereosinophilic syndrome
Inpharma, Vol. 1, Iss. 1381, 2003-01 ,pp. :